Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Dermatology

Building Your Care Team and Preparing for Your First Visit

At a Glance

Because CTCL is a rare disease, the most effective care requires a multidisciplinary team including a dermatologist, hematologist-oncologist, and dermatopathologist. When preparing for your first major visit, always gather and bring your physical biopsy slides and complete medical records.

Because Primary Cutaneous T-Cell Lymphoma (CTCL) is a rare disease that lives at the intersection of dermatology and oncology, a single doctor rarely has all the answers. Research consistently shows that a multidisciplinary team (MDT) approach is essential for providing the best care, particularly for accurate staging and managing complex symptoms like pain and itching [1][2][3].

Assembling Your Team

A comprehensive care team for CTCL should include several key specialists working in coordination [1][4]:

  • Dermatologist: Often the “first responder,” they manage skin-directed therapies (like light therapy and medicated gels) and monitor the skin for changes or infections [5][3].
  • Hematologist-Oncologist: A specialist in blood cancers who manages systemic therapies (pills or IV medications) if the disease moves beyond the skin or becomes resistant to topical treatments [4][6].
  • Dermatopathologist: A behind-the-scenes doctor who interprets your skin biopsies. For rare conditions like CTCL, having an expert who sees these cases frequently is critical for a correct diagnosis [7][8].
  • Specialized Nursing: Nurses who understand the unique wound care, skin toxicity, and symptom management (like the “bone-deep” itch) associated with CTCL [3][9].
  • Supportive Care: Because CTCL is a chronic condition that affects your appearance, access to psychosocial support and palliative specialists can help manage the emotional and physical burden of the disease [10][11].

Vetting Your Care Team

Not all oncologists or dermatologists are familiar with the nuances of CTCL. When visiting a new doctor, use these questions to ensure they have the necessary expertise:

  1. “Do you participate in a multidisciplinary tumor board for cutaneous lymphomas?” Expert centers regularly hold meetings where dermatologists and oncologists discuss patient cases together [1][4].
  2. “How many patients with CTCL do you treat?” Rare diseases require frequent practice; you want a team that sees more than just an occasional case.
  3. “Are you following the latest NCCN or EORTC guidelines for staging and treatment?” This ensures your care aligns with current global standards [12][13].

Preparing for Your First Major Visit

To get the most out of an initial consultation or a second opinion at a “Center of Excellence,” you should bring a complete “diagnostic package.” Having these items ready allows the new team to verify your diagnosis without repeating every test [14][15].

Physical Items and Records Checklist

  • Biopsy Slides and Blocks: You have the right to request your original glass slides and the “paraffin blocks” (the actual tissue samples) from the hospital where your biopsy was performed. Tip: You will typically need to sign a specific material release form directly at the pathology lab/department of the facility where the biopsy was performed—regular medical records departments usually do not handle physical slides. [14][2].
  • Pathology Reports: Bring every report you have received, even if they were initially inconclusive [7].
  • Flow Cytometry Results: These blood tests are essential for checking for Sézary cells and determining your “B” (blood) stage [16][17].
  • Imaging Reports: If you have had CT, PET, or MRI scans, bring the written reports and, if possible, the images on a disc [15].
  • Treatment History: Create a simple list of every topical cream, light therapy, or pill you have used for your skin, including for how long and whether it helped [5].
  • Clinical Photos: If your rash has changed over time, photos can help the doctor understand the “evolution” of your symptoms [14].

Common questions in this guide

What specialists should be on my CTCL care team?
A comprehensive CTCL care team should include a dermatologist for skin-directed therapies, a hematologist-oncologist for systemic treatments, and a specialized dermatopathologist. Specialized nurses and supportive care experts are also vital for symptom management.
What do I need to bring to my first appointment with a CTCL specialist?
You should bring a complete diagnostic package to avoid repeat testing. This includes your physical biopsy slides and tissue blocks, all pathology reports, flow cytometry results, imaging reports, and a timeline of any past treatments.
Why do I need to bring my physical biopsy slides for a second opinion?
Bringing your original glass slides and tissue blocks allows the new medical team to independently verify your diagnosis without having to perform another painful biopsy. You will typically need to sign a release form directly at the lab where the biopsy was performed.
What is a multidisciplinary tumor board for cutaneous lymphomas?
A multidisciplinary tumor board is a formal meeting where experts from different specialties, such as dermatology, oncology, and pathology, collaborate on complex cases. This ensures your staging and treatment plan is reviewed from multiple medical perspectives.
Who handles the severe itching caused by CTCL?
Severe itching is typically managed by your dermatologist or specialized oncology nurses. They understand the unique nature of CTCL-related nerve itch and can recommend advanced skin-directed therapies when standard moisturizing creams are no longer effective.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does your hospital or center have a dedicated multidisciplinary tumor board that meets regularly to discuss Cutaneous Lymphoma cases?
  2. 2.Approximately how many patients with Mycosis Fungoides or Sézary Syndrome do you personally treat or manage each year?
  3. 3.What is your specific protocol for managing severe nerve itch when standard creams aren't working?
  4. 4.Who will be my primary point of contact for managing day-to-day symptoms like intense itching or skin infections—is there a specialized nurse or dermatologist on the team?
  5. 5.Do you work with a dermatopathologist who specializes specifically in skin lymphomas to review my biopsies?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides.

    Vitiello P, Sagnelli C, Ronchi A, et al.

    Healthcare (Basel, Switzerland) 2023; (11(4)) doi:10.3390/healthcare11040614.

    PMID: 36833148
  2. 2

    Cutaneous T cell lymphoma.

    Dummer R, Vermeer MH, Scarisbrick JJ, et al.

    Nature reviews. Disease primers 2021; (7(1)):61 doi:10.1038/s41572-021-00296-9.

    PMID: 34446710
  3. 3

    "Knock Me Out": The Challenges of Managing Pain Due to Cutaneous T Cell Lymphomas: A Case Report.

    Pandey S, Dolan A, Norton-Westbrook M, Desai AV

    Journal of palliative medicine 2022; (25(11)):1740-1746 doi:10.1089/jpm.2021.0561.

    PMID: 35420490
  4. 4

    Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee.

    Damaj G, de Masson A, Dreger P, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2025; doi:10.1111/jdv.70042.

    PMID: 41031482
  5. 5

    Skin Directed Therapy in Cutaneous T-Cell Lymphoma.

    Tarabadkar ES, Shinohara MM

    Frontiers in oncology 2019; (9()):260 doi:10.3389/fonc.2019.00260.

    PMID: 31032224
  6. 6

    Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.

    Ollila TA, Sahin I, Olszewski AJ

    OncoTargets and therapy 2019; (12()):1085-1094 doi:10.2147/OTT.S165615.

    PMID: 30799938
  7. 7

    Histopathological Patterns in Mycosis Fungoides: A Cross-Sectional Study.

    Mohaghegh F, Shayan M, Rajabi P, et al.

    Journal of skin cancer 2025; (2025()):9995443 doi:10.1155/jskc/9995443.

    PMID: 41127440
  8. 8

    Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping.

    Pulitzer MP, Horna P, Almeida J

    Cytometry. Part B, Clinical cytometry 2021; (100(2)):132-138 doi:10.1002/cyto.b.21888.

    PMID: 32516521
  9. 9

    Non-Hodgkin Lymphoma: Examining Mycosis Fungoides and Sézary Syndrome in the Context of Oncology Nursing.

    Ow KV, Brant JM

    Clinical journal of oncology nursing 2021; (25(5)):555-562 doi:10.1188/21.CJON.555-562.

    PMID: 34533520
  10. 10

    Understanding itch in cutaneous T-cell lymphoma: Exploring the impact of comorbidities, treatment regimens, and racial differences on quality of life.

    Joshi TP, Duvic M

    JAAD international 2023; (10()):55-56 doi:10.1016/j.jdin.2022.11.006.

    PMID: 36636103
  11. 11

    Health-related quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomas: A multicentric study in 100 patients.

    Schirren AEC, Albrecht JD, Melchers S, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2024; (38(5)):954-966 doi:10.1111/jdv.19799.

    PMID: 38279594
  12. 12

    Management Strategies for Mycosis Fungoides in India.

    Raychaudhury T

    Indian journal of dermatology 2017; (62(2)):137-141 doi:10.4103/ijd.IJD_71_17.

    PMID: 28400632
  13. 13

    Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management.

    Miyashiro D, Sanches JA

    Frontiers in oncology 2023; (13()):1141108 doi:10.3389/fonc.2023.1141108.

    PMID: 37124514
  14. 14

    Cutaneous T-cell lymphoma: diagnosing subtypes and the challenges.

    Hague C, Farquharson N, Menasce L, et al.

    British journal of hospital medicine (London, England : 2005) 2022; (83(4)):1-7 doi:10.12968/hmed.2021.0149.

    PMID: 35506718
  15. 15

    Coexistence of large cell transformed mycosis fungoides and diffuse large B-cell lymphoma in one patient.

    Rohan TZ, Suriano J, Tekmen V, et al.

    Journal of cutaneous pathology 2024; (51(10)):761-766 doi:10.1111/cup.14673.

    PMID: 38967043
  16. 16

    It is time to adopt a multicolor immunophenotyping approach to evaluate blood for Sézary syndrome and mycosis fungoides.

    Craig FE

    Cytometry. Part B, Clinical cytometry 2021; (100(2)):125-128 doi:10.1002/cyto.b.21872.

    PMID: 32083391
  17. 17

    Serum cell-free DNA as a new biomarker in cutaneous T-cell lymphoma.

    Mizuno Y, Shibata S, Miyagaki T, et al.

    The Journal of dermatology 2022; (49(11)):1124-1130 doi:10.1111/1346-8138.16520.

    PMID: 35821652

This page provides educational information on assembling a care team for CTCL. It is not intended as medical advice. Always consult your healthcare providers for specific treatment planning and symptom management.

Get notified when new evidence is published on Primary cutaneous T-cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.